Drug intelligence / Profile preview

gramicidin s + cetylpyridinium chloride + oxybuprocaine

Development stage
Unknown
Lead developer
Valenta Pharm
Modality
Peptides, Small Molecules
Administration
Topical, Oropharyngeal, Oral (lozenge; Local Action Only)
01

Overview

**Gramicidin s + cetylpyridinium chloride + oxybuprocaine** is a topical combination drug formulated for **symptomatic and antimicrobial treatment of acute inflammatory and infectious conditions of the oropharynx**, such as pharyngitis and tonsillitis. - **Gramicidin S** is a **cyclic peptide antibiotic** with broad-spectrum bactericidal activity, particularly effective against gram-positive organisms. It disrupts bacterial cell membrane integrity, leading to cell lysis. - **Cetylpyridinium chloride (CPC)** is a **quaternary ammonium compound antiseptic** that provides rapid bactericidal and fungicidal action, especially on gram-positive bacteria and yeasts. It works by disrupting microbial membranes through its cationic surfactant properties, also offering substantivity (retention and continued activity in the mouth)[1][2][3][5][6]. - **Oxybuprocaine** is a **local anesthetic** (an ester class compound), providing fast, reversible analgesia at the site of application by blocking voltage-gated sodium channels on sensory neurons, interfering with pain signal transmission. The combination is used for short-term relief of pain, inflammation, and microbial burden during acute pharyngeal inflammatory processes. It is most commonly administered as **lozenges or sprays** for oropharyngeal topical use.

Brand names
Grammidin with anesthetic
Other names
Grammidin with anesthetic spray
02

Targets

NaV (Voltage-gated sodium channels)Gtf (Streptococcus mutans glucosyltransferase)

Beyond the preview

Go deeper on gramicidin s + cetylpyridinium chloride + oxybuprocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gramicidin s + cetylpyridinium chloride + oxybuprocaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call